# US 2023/0058971 A1 · Extended release microparticles and suspensions thereof for medical therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0058971 A1
- Document ID: US20230058971A1
- Status: Published application
- Kind: A1
- Application number: 17/530,347
- Filed: 2021-11-18
- Published: 2023-02-23
- Earliest claimed: 2017-05-10
- Assignees: Graybug Vision, Inc.
- Applicants: Graybug Vision, Inc.
- Inventors: Ming Yang; Jeffrey L. Cleland; Yun Yu; Weiling Yu; Joshua Kays
- Web page: https://patentgrep.com/patent/US20230058971A1

## CPC

- A61K 47/54: the modifying agent being an organic compound
- A61K 9/0051: {Ocular inserts or implants}
- A61K 9/5031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)}
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/216: of acids having aromatic rings, e.g. benactizyne, clofibrate
- A61K 31/382: having six-membered rings, e.g. thioxanthenes (thiothixene A61K31/496)
- A61K 31/404: Indoles, e.g. pindolol
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/498: Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/542: ortho- or peri-condensed with heterocyclic ring systems
- A61P 27/02: Ophthalmic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An improved microparticle or lyophilized or otherwise reconstitutable microparticle composition thereof for medical therapy, including ocular therapy.

## Claims

### Claim 1

A method for the treatment of an ocular disorder selected from glaucoma, wet-age related macular degeneration, dry-age related macular degeneration, or a disorder related to an increase in intraocular pressure comprising suprachoroidal administration of an effective amount of solid aggregating biodegradable microparticles optionally in a pharmaceutically acceptable carrier wherein the solid aggregating biodegradable microparticles comprise a prodrug of a therapeutically active compound encapsulated in (a) poly(lactic-co-glycolic acid) (PLGA) and/or polylactic acid (PLA) and (b) poly(lactic-co-glycolic acid) conjugated to polyethylene glycol (PLGA-PEG), and a surfactant, wherein the microparticles:
(i) have a mean diameter between 10 μm and 60 μm;
(ii) have been surface-modified with a surface treatment agent to partially degrade surface polymer at a temperature less than about 18° C. wherein the surface treatment agent comprises an aqueous base and an organic solvent;
(iii) aggregate in vivo to form at least one larger pellet in vivo that provides sustained drug delivery in vivo for at least three months; and
(iv) wherein the prodrug is selected from the formula:
or a pharmaceutically acceptable salt thereof
wherein
x and y are independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; and
x′ and y′ are independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10.

### Claim 2 (depends on 1)

The method of claim 1, wherein x and y are independently selected from 1, 2, 3, 4, 5, and 6.

### Claim 3 (depends on 1)

The method of claim 1, wherein x′ and y′ are independently selected from 1, 2, 3, 4, 5, and 6.

### Claim 4 (depends on 1)

The method of claim 1, wherein y is 2, 3, or 4 and y′ is 2, 3, or 4.

### Claim 5 (depends on 1)

The method of claim 1, wherein the prodrug is of the formula
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 5)

The method of claim 5, wherein y is 2, 3, or 4 and y′ is 2, 3, or 4.

### Claim 7 (depends on 6)

The method of claim 6, wherein the prodrug is of the formula
or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 6)

The method of claim 6, wherein the prodrug is of the formula
or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 1)

The method of claim 1, wherein at least one pellet provides sustained drug delivery for at least 4 months.

### Claim 10 (depends on 1)

The method of claim 1, wherein at least one pellet provides sustained drug delivery for at least 5 months.

### Claim 11 (depends on 1)

The method of claim 1, wherein at least one pellet provides sustained drug delivery for at least 6 months.

### Claim 12 (depends on 1)

The method of claim 1, wherein the solid aggregating biodegradable microparticles have a mean diameter between about 20 and 50 μm.

### Claim 13 (depends on 1)

The method of claim 1, wherein the solid aggregating biodegradable microparticles have a mean diameter between about 20 and 40 μm.

### Claim 14 (depends on 1)

The method of claim 1, wherein the solid aggregating biodegradable microparticles have a mean diameter between about 20 and 30 μm.

### Claim 15 (depends on 1)

The method of claim 1, wherein the solid aggregating biodegradable microparticles have a mean diameter between about 25 and 40 μm.

### Claim 16 (depends on 1)

The method of claim 1, wherein the solid aggregating biodegradable microparticles have a mean diameter between about 25 and 35 μm.

### Claim 17 (depends on 1)

The method of claim 1, wherein the aqueous base is a hydroxide base.

### Claim 18 (depends on 1)

The method of claim 1, wherein the aqueous base is sodium hydroxide.

### Claim 19 (depends on 1)

The method of claim 1, wherein the aqueous base is potassium hydroxide.

### Claim 20 (depends on 17)

The method of claim 17, wherein the organic solvent is an alcohol.

### Claim 21 (depends on 20)

The method of claim 20, wherein the alcohol is ethanol.

### Claim 22 (depends on 20)

The method of claim 20, wherein the alcohol is methanol.

### Claim 23 (depends on 21)

The method of claim 21, wherein the surface treatment agent comprises ethanol and sodium hydroxide.

### Claim 24 (depends on 1)

The method of claim 1, wherein the surface has been modified at a temperature not more than 16° C.

### Claim 25 (depends on 1)

The method of claim 1, wherein the surface has been modified at a temperature not more than 10° C.

### Claim 26 (depends on 1)

The method of claim 1, wherein the surface has been modified at a temperature not more than 8° C.

### Claim 27 (depends on 1)

The method of claim 1, wherein the surface has been modified at a temperature not more than 5° C.

### Claim 28 (depends on 1)

The method of claim 1 for the treatment of glaucoma.

### Claim 29 (depends on 1)

The method of claim 1 for the treatment of wet-age related macular degeneration.

### Claim 30 (depends on 1)

The method of claim 1 for the treatment of dry-age related macular degeneration.

### Claim 31 (depends on 1)

The method of claim 1 for the treatment of a disorder related to an increase in intraocular pressure.

### Claim 32 (depends on 1)

The method of claim 1 wherein the ocular disorder for treatment is in a human.
